Skip to main content
SpringerLink
Log in

Strahlentherapie endokriner Tumoren

Radiotherapy for endocrine tumors

  • Leitthema
  • Published:
Die Onkologie Aims and scope

Zusammenfassung

Hintergrund

Gemeinsam mit neuen Systemtherapien nimmt die Strahlentherapie in der Behandlung endokriner und neuroendokriner Tumoren weiterhin ihren Platz ein. Die Weiterentwicklung der Strahlentherapietechnik ermöglichte deren Einzug in die Behandlung seltener Tumorentitäten.

Material und Methoden

Es erfolgte eine selektive PubMed-Recherche und die Berücksichtigung nationaler und internationaler Leitlinien.

Ergebnisse

Endokrine und neuroendokrine Tumoren (NET) werden selten primär radioonkologisch behandelt. In der Behandlung anaplastischer Schilddrüsenkarzinome und aggressiver Hypophysentumoren stellt die Strahlentherapie jedoch eine feste Therapiesäule im multimodalen Konzept. Lokal fortgeschrittene NET können mit einer simultanen Radiochemotherapie behandelt werden. Das Instrumentarium der lokal ablativen Strahlentherapie findet bei Oligometastasierung Anwendung. In palliativen Situationen wird die Strahlentherapie mit dem Ziel der Symptomlinderung erfolgreich eingesetzt.

Schlussfolgerung

Trotz Fortschritten in der Systemtherapie endokriner und neuroendokriner Tumoren kann das Fachgebiet der Strahlentherapie und Radioonkologie ein breites Therapiespektrum von der kurativen bis zur palliativen Situation einschließlich der Oligometastasierung offerieren. Der Zeitpunkt des Einsatzes der Strahlentherapie sollte interdisziplinär festgelegt werden.

Abstract

Background

Even with the advent of new systemic therapy options, radiotherapy keeps its place for the treatment of endocrine and neuroendocrine tumors. The advancement of radiotherapy technology has enabled its advent into the treatment of rare tumor entities.

Materials and methods

A selective PubMed search was performed and national and international guidelines were taken into consideration.

Results

Endocrine and neuroendocrine tumors are rarely treated by definitive radiotherapy. For anaplastic thyroid carcinomas and aggressive pituitary tumors, radiotherapy represents a cornerstone of multimodal treatment. Locally advanced neuroendocrine tumors (NET) can be treated with concomitant radiochemotherapy. Stereotactic ablative radiotherapy is applied in oligometastatic cases. In palliative situations, radiotherapy is successfully used for symptom relief.

Conclusion

Despite advances in systemic therapy options for treatment of endocrine and neuroendocrine tumors, the field of radiation therapy continues to offer a broad spectrum of therapies from curative to palliative situations, including oligometastasis. The decision for radiotherapy treatment should be made by a multidisciplinary team.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Azrif M, Slevin NJ, Sykes AJ et al (2008) Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Radiother Oncol 89:105–113

    Article  Google Scholar 

  2. Bible KC, Kebebew E, Brierley J et al (2021) 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31:337–386

    Article  Google Scholar 

  3. Chapman CH (2018) Thyroid cancer. In: Hansen EKRIM (Hrsg) Handbook of evidence-based radiation oncology. Springer, Cham, Switzerland, S 243–258

    Chapter  Google Scholar 

  4. Chintakuntlawar AV, Yin J, Foote RL et al (2019) A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer. Thyroid 29:1615–1622

    Article  CAS  Google Scholar 

  5. Chow SM, Law SC, Mendenhall WM et al (2002) Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 52:784–795

    Article  Google Scholar 

  6. Denis F, Garaud P, Bardet E et al (2003) Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55:93–98

    Article  Google Scholar 

  7. Epstein JB, Lunn R, Le N et al (1998) Periodontal attachment loss in patients after head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86:673–677

    Article  CAS  Google Scholar 

  8. Filetti S, Durante C, Hartl D et al (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1856–1883

    Article  CAS  Google Scholar 

  9. Foote RL, Molina JR, Kasperbauer JL et al (2011) Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 21:25–30

    Article  Google Scholar 

  10. Fussey JM, Crunkhorn R, Tedla M et al (2016) External beam radiotherapy in differentiated thyroid carcinoma: a systematic review. Head Neck 38(1):E2297–2305

    Article  Google Scholar 

  11. Haddad R, Mahadevan A, Posner MR et al (2005) Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. Am J Clin Oncol 28:104

    Article  Google Scholar 

  12. Haymart MR, Banerjee M, Yin H et al (2013) Marginal treatment benefit in anaplastic thyroid cancer. Cancer 119:3133–3139

    Article  Google Scholar 

  13. Kikuchi Y, Shimada H, Yamaguchi K et al (2019) Systematic review of case reports of Japanese esophageal neuroendocrine cell carcinoma in the Japanese literature. Int Cancer Conf J 8:47–57

    Article  Google Scholar 

  14. Leitlinienprogramm Onkologie (2021) S3-Leitlinie Diagnostik und Therapie des Mundhöhlenkarzinoms 3.0. https://www.leitlinienprogramm-onkologie.de/leitlinien/mundhoehlenkarzinom/ (AWMF Registernummer: 007/100OL). Zugegriffen: 08.02.2022

  15. Milano MT, Biswas T, Simone CB 2nd et al (2021) Oligometastases: history of a hypothesis. Ann Palliat Med 10:5923–5930

    Article  Google Scholar 

  16. Milker-Zabel S, Debus J, Thilmann C et al (2001) Fractionated stereotactically guided radiotherapy and radiosurgery in the treatment of functional and nonfunctional adenomas of the pituitary gland. Int J Radiat Oncol Biol Phys 50:1279–1286

    Article  CAS  Google Scholar 

  17. Milker-Zabel S, Zabel A, Huber P et al (2004) Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma. Int J Radiat Oncol Biol Phys 59:1088–1096

    Article  Google Scholar 

  18. Minniti G, Gilbert DC, Brada M (2009) Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord 10:135–144

    Article  CAS  Google Scholar 

  19. Minniti G, Osti MF, Niyazi M (2016) Target delineation and optimal radiosurgical dose for pituitary tumors. Radiat Oncol 11:135

    Article  Google Scholar 

  20. Minniti G, Traish D, Ashley S et al (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90:800–804

    Article  CAS  Google Scholar 

  21. Nccn (2021) Neuroendocrine and adrenal tumors. www.NCCN.org. Zugegriffen: 08.02.2022

  22. Noad R, Narayanan KR, Howlett T et al (2004) Evaluation of the effect of radiotherapy for pituitary tumours on cognitive function and quality of life. Clin Oncol 16:233–237

    Article  CAS  Google Scholar 

  23. Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058

    Article  Google Scholar 

  24. Romesser PB, Sherman EJ, Shaha AR et al (2014) External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. J Surg Oncol 110:375–382

    Article  Google Scholar 

  25. Schwartz DL, Lobo MJ, Ang KK et al (2009) Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 74:1083–1091

    Article  Google Scholar 

  26. Sherman EJ, Lim SH, Ho AL et al (2011) Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 101:425–430

    Article  CAS  Google Scholar 

  27. Sorbye H (2021) High-grade gastroenteropancreatic neuroendocrine neoplasms. Uptodate. Wolters Kluwer

    Google Scholar 

  28. Troch M, Koperek O, Scheuba C et al (2010) High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 95:E54–57

    Article  Google Scholar 

  29. Wu XL, Hu YH, Li QH et al (1987) Value of postoperative radiotherapy for thyroid cancer. Head Neck Surg 10:107–112

    Article  CAS  Google Scholar 

  30. Zelefsky MJ, Yamada Y, Greco C et al (2021) Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer. Int J Radiat Oncol Biol Phys 110:672–679

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinikum rechts der Isar, Klinik und Poliklinik für RadioOnkologie und Strahlentherapie, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland

    Steffi Ulrike Pigorsch

Authors
  1. Steffi Ulrike Pigorsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steffi Ulrike Pigorsch.

Ethics declarations

Interessenkonflikt

S.U. Pigorsch gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pigorsch, S.U. Strahlentherapie endokriner Tumoren. Onkologie 28, 687–700 (2022). https://doi.org/10.1007/s00761-022-01207-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-022-01207-7

Schlüsselwörter

Keywords

Search

Navigation